The content on this site is intended for healthcare professionals only
Prof Mejean presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from a trial in which 450 patients with metastatic renal cell carcinoma (mRCC) were randomised to receive either TKI inhibitor sunitinib alone or sunitinib and nephrectomy.
The trial found that survival between the two arms was no different, though it is noted that for patients ineligible for systemic treatment surgery remains the gold standard.
For more on these results, watch Dr Mejean discuss the findings with ecancer here, and read our news coverage here.
Slides from this presentation are available here.
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients
Adjuvant radiotherapy has no benefit following radical prostatectomy
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
Short-course radiation as effective as standard treatment for breast cancer patients choosing reconstruction after mastectomy
OncoAlert Round Up for September 15-21, 2023
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
